**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 1. (previously amended) A compound of formula (I)(B):




wherein

$X_1$ is $CR_1$, wherein $R_1$ is H, halo, amino, or nitro; and $X_2$ is $NR_3$;

$R_3$ is H, $-SO_2$ ($C_{1-6}$ alkyl), $-SO_2$ phenyl, (C=O)($C_{1-6}$ alkyl), or -W'Z';

W' is a covalent bond, (C=O), $SO_2$, or $C_{1-6}$ alkyl;

Z' is $C_{1-6}$ alkyl, $C_{1-6}$ alkoxy, $C_{3-8}$ cycloalkyl, or a heterocyclic radical selected from the group consisting of thiazoylyl, furyl, pyranyl, isobenzofuranyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolyl, furazanyl, pyrrolidinyl, pyrrolinyl, imdazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidyl, piperazinyl, indolinyl, and morpholinyl; or Z' is $NR_{13}R_{14}$where each of $R_{13}$ and $R_{14}$ is independently selected from $C_{1-6}$ alkyl, $C_{2-6}$ alkenyl, phenyl, benzyl, $C_{3-8}$ cycloalkyl, and a heterocyclic radical selected from the group consisting of thiazoylyl, furyl, pyranyl, isobenzofuranyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolyl, furazanyl, pyrrolidinyl, pyrrolinyl, imdazolidinyl, imidazolinyl, pyrazolidinyl,

pyrazolinyl, piperidyl, piperazinyl, indolinyl, and morpholinyl each of $R_5$, $R_6$, $R_7$ and $R_8$ is independently H, C $_{1-6}$ alkyl, $C_{1-6}$ alkoxy, halo, nitro, or amino;

one of $R_a$, $R_b$, $R_c$, $R_d$, and $R_e$ is WZ and the others are independently selected from H, C $_{1-6}$ alkyl, C $_{1-6}$ alkoxy, halo, nitro, and amino;

W is -O-, O-$R_9$, $NR_{10}$, -(CO)(O)$R_9$, -O (CO)$R_9$, -(CO)$NR_{10}$, or -N($R_{10}$)-CO-$R_9$, wherein $R_9$ is C $_{1-6}$ alkylene, C $_{2-6}$ alkynylene, C $_{2-6}$ alkenylene, phenylene, or a heterocyclic bivalent radical selected from the group consisting of thiazoylyl, furyl, pyranyl, isobenzofuranyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolyl, furazanyl, pyrrolidinyl, pyrrolinyl, imdazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidyl, piperazinyl, indolinyl, and morpholinyl, and $R_{10}$ is H, C $_{1-6}$ alkyl, C $_{2-6}$ alkynyl, C $_{2-6}$ alkenyl, phenyl, or a heterocyclic radical selected from the group consisting of thiazoylyl, furyl, pyranyl, isobenzofuranyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolyl, furazanyl, pyrrolidinyl, pyrrolinyl, imdazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidyl, piperazinyl, indolinyl, and morpholinyl;

Z is a heterocyclic radical selected from the group consisting of thiazoylyl, furyl, pyranyl, isobenzofuranyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolyl, furazanyl, pyrrolidinyl, pyrrolinyl, imdazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidyl, piperazinyl, indolinyl, and morpholinyl, provided that when Z is pyrrolyl, piperidyl or morpholinyl the heterocyclic radical is attached through a ring

carbon; or Z is $NR_{11}R_{12}$ where each of $R_{11}$ and $R_{12}$ is independently selected from H, $C_{1-6}$ alkyl, phenyl, benzyl, $C_{3-8}$ cycloalkyl, and a heterocyclic radical selected from the group consisting of thiazoylyl, furyl, pyranyl, isobenzofuranyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolyl, furazanyl, pyrrolidinyl, pyrrolinyl, imdazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidyl, piperazinyl, indolinyl, and morpholinyl; or $NR_{11}R_{12}$ taken together is a $C_{6-8}$ cycloalkylimino radical; each of the above hydrocarbyl or heterocyclic groups being optionally substituted with between 1 and 3 substituents selected from $C_{1-3}$ alkyl, $C_{1-3}$ alkoxy, halo, hydroxy, phenyl, and phenyl($C_{1-3}$ alkyl); and wherein each of the above heterocyclic groups may be attached to the rest of the molecule by a carbon atom or a heteroatom;
provided that $R_b$, $R_d$, $R_5$, $R_6$, $R_7$ and $R_8$, if halo, are selected from chloro;
or a pharmaceutically acceptable salt, amide, ester, or hydrate thereof.

2. (original) A compound of claim 1, wherein $R_3$ is H or $C_{1-3}$ alkyl.

3. (original) A compound of claim 1, wherein $R_3$ is -(C=O)$C_{1-6}$ alkyl.

4. (original) A compound of claim 1, wherein $R_3$ is -$SO_2$($C_{1-3}$ alkyl).

5. (original) A compound of claim 4 wherein $R_3$ is methylsulfonyl.

6. (original) A compound of claim 1, wherein W' is a covalent bond.

7. (original) A compound of claim 1, wherein W' is $SO_2$ or (C=O).

8. (original) A compound of claim 1, wherein $R_c$ is WZ.

9. (original) A compound of claim 1, wherein $R_b$ or $R_d$ is WZ.

10. (original) A compound of claim 1, wherein W is ethoxy, propoxy, or butoxy.

11. (original) A compound of claim 1, wherein W is -O-.

12. (original) A compound of claim 1, wherein one of $R_b$, $R_c$, and $R_e$ is WZ and the others are independently selected from H, methyl, ethyl, methoxy, ethoxy, amino, nitro, and halo; and $R_a$ and $R_d$ are each independently H or methyl.

13. (original) A compound of claim 1, wherein at least two of the following apply: $R_c$ is WZ; W is propoxy or ethoxy; and Z is N-piperidino, 2-(N-methyl)pyrrolidino, or N,N-dimethyl.

14. (previously amended) A compound of claim 1, wherein Z is pyrrolidino, N-methyl-pyrrolidino, pyridyl, thiazoyl, piperidino, or $NR_{11}R_{12}$ where each of $R_{11}$ and $R_{12}$ is independently selected from H, $C_{1-6}$ alkyl, phenyl, benzyl, $C_{3-6}$ cycloalkyl, and a heterocyclic radical selected from the group consisting of thiazoylyl, furyl, pyranyl, isobenzofuranyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolyl, furazanyl, pyrrolidinyl, pyrrolinyl, imdazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidyl, piperazinyl, indolinyl, and morpholinyl or taken together with the N form a $C_{6-8}$ cycloalkylamino radical.

15. (previously amended) A compound of claim 1, wherein one of $R_b$, $R_c$, and $R_e$ is WZ and the others are independently selected from H, methyl, ethyl, methoxy, ethoxy, amino, and halo; and $R_a$ and $R_d$ are each independently H or methyl;
W is -O- or C $_{1-3}$ alkoxy;
Z is pyrrolidino, N-methylpyrrolidino, pyridyl, thiazoyl, piperidino, piperazino, N-methylpiperazino,or $NR_{11}R_{12}$ where each of $R_{11}$ and $R_{12}$ is independently selected from H, C $_{1-2}$ alkyl, phenyl, benzyl, C $_{3-8}$ cycloalkyl, and a heterocyclic radical selected from the group consisting of thiazoylyl, furyl, pyranyl, isobenzofuranyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolyl, furazanyl, pyrrolidinyl, pyrrolinyl, imdazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidyl, piperazinyl, indolinyl, and morpholinyl; each of $R_6$ and $R_7$ are each independently H, methyl, methoxy, or ethoxy; each of $R_5$ and $R_8$ is H.

16. (original) A compound of claim 15, wherein $R_3$ is H or -$SO_2$ (C $_{1-6}$ alkyl).

17. (original) A compound of claim 15, wherein $R_3$ is $SO_2$ (phenyl) and (C=O)(C $_{1-6}$ alkyl).

18. (previously amended) A compound of claim 15, selected from 2-[4-[2-[1-(methyl)-2-pyrrolidinyl]ethoxy]phenyl)-1H-indole, 2-[4-[2-[1-(methyl)-2-pyrrolidinyl]ethoxy]phenyl)-1-(methylsulfonyl) -1H-indole, 2-(4-(3-(4-methylpiperazino)propoxy)-phenyl)indole; and 1-(methylsulfonyl)-2-(4-(3-(4-methylpiperazino)-propoxy)phenyl)indole; or a pharmaceutically acceptable salt, amide, ester, or hydrate thereof.

19. (cancelled)

20. (original) A pharmaceutical composition comprising a compound of formula (I)B and a pharmaceutically acceptable carrier.

21. (previously amended) A pharmaceutical composition of claim 20, wherein said compound has a formula wherein: one of $R_b$, $R_c$, and $R_e$ is WZ and the others are independently selected from H, methyl, ethyl, methoxy, ethoxy, amino, and halo;
$R_a$ and $R_d$ are each independently H or methyl;
W is -O- or $C_{1-3}$ alkoxy;
Z is pyrrolidino, N-methylpyrrolidino, pyridyl, thiazoyl, piperidino, or $NR_{11}R_{12}$ where each of $R_{11}$ and $R_{12}$ is independently selected from H, $C_{1-2}$ alkyl, phenyl, benzyl, $C_{3-8}$ cycloalkyl, and a heterocyclic radical selected from the group consisting of thiazoylyl, furyl, pyranyl, isobenzofuranyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolyl, furazanyl, pyrrolidinyl, pyrrolinyl, imdazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidyl, piperazinyl, indolinyl, and morpholinyl; and
$R_6$ and $R_7$ are each independently H, methyl, methoxy, or ethoxy.

22. (previously amended) A pharmaceutical composition of claim 21, wherein said compound has a formula selected from 2-[4-[2-[1-(methyl)-2-pyrrolidinyl]ethoxy]phenyl)-1H-indole; 2-[4-[2-[1-(methyl)-2-pyrrolidinyl]ethoxy]phenyl)-1-(methylsulfonyl) -1H-indole; 2-[3-[3-Piperidinopropoxy]phenyl)-1-(methylsulfonyl)-1H-indole; 2-(4-(3-(4-methylpiperazino)propoxy)-phenyl)indole; and

1-(methylsulfonyl)-2-(4-(3-(4-methylpiperazino)-propoxy)phenyl)indole; or a pharmaceutically acceptable salt, amide, ester, or hydrate thereof.

23. (cancelled)

24. (cancelled)

25. (cancelled)

26. (cancelled)

27. (cancelled)

28. (cancelled)

29. (cancelled)

30. (cancelled)

31. (cancelled)

32. (cancelled)

33. (new) A compound of claim 1 selected from 2-[4-[1-(methyl)-4-piperidinyl]oxyphenyl]-1-(methylsulfonyl)-1H-indole;
2-[4-[1-(methyl)-4-piperidinyl]oxyphenyl]-1H-indole;
2-[4-[3-dimethylaminopropoxy]phenyl]-1-(methylsulfonyl)-1H-indole;
2-[4-[3-dimethylaminopropoxy]phenyl]-1H-indole;
2-[4-[4-pyridinyl]methoxyphenyl]-1-(methylsulfonyl)-1H-indole;
2-[4-[2-diethylaminoethoxy]phenyl]-1-(methylsulfonyl)-1H-indole;

2-[4-[2-diethylaminoethoxy]phenyl]-1H-indole;
2-[4-[2-(2-pyridinyl)ethoxyphenyl]-1-(methylsulfonyl)-1H-indole;
and 2-[4-[2-(2-pyridinyl)ethoxyphenyl]-1H-indole; or a
pharmaceutically acceptable salt, amide, ester, or hydrate thereof.

34. (new) A pharmaceutical composition of claim 20, wherein said compound has a formula selected from 2-[4-[1-(methyl)-4-piperidinyl]oxyphenyl]-1-(methylsulfonyl)-1H-indole;
2-[4-[1-(methyl)-4-piperidinyl]oxyphenyl]-1H-indole;
2-[4-[3-dimethylaminopropoxy]phenyl]-1-(methylsulfonyl)-1H-indole;
2-[4-[3-dimethylaminopropoxy]phenyl]-1H-indole;
2-[4-[4-pyridinyl]methoxyphenyl]-1-(methylsulfonyl)-1H-indole;
2-[4-[2-diethylaminoethoxy]phenyl]-1-(methylsulfonyl)-1H-indole;
2-[4-[2-diethylaminoethoxy]phenyl]-1H-indole;
2-[4-[2-(2-pyridinyl)ethoxyphenyl]-1-(methylsulfonyl)-1H-indole;
and 2-[4-[2-(2-pyridinyl)ethoxyphenyl]-1H-indole; or a
pharmaceutically acceptable salt, amide, ester, or hydrate thereof.